[HTML][HTML] SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
S Pilz, V Theiler-Schwetz, C Trummer, R Krause… - Environmental …, 2022 - Elsevier
Seroprevalence surveys suggest that more than a third and possibly more than half of the
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …
[HTML][HTML] SARS-CoV-2: Evolution and emergence of new viral variants
VR Flores-Vega, JV Monroy-Molina… - Viruses, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent
responsible for the coronavirus disease 2019 (COVID-19). The high rate of mutation of this …
responsible for the coronavirus disease 2019 (COVID-19). The high rate of mutation of this …
Long-term immune response to SARS-CoV-2 infection among children and adults after mild infection
C Di Chiara, A Cantarutti, P Costenaro… - JAMA network …, 2022 - jamanetwork.com
Importance Understanding the long-term immune response against SARS-CoV-2 infection
in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV …
in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV …
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
J Van Elslande, M Oyaert, N Lorent… - … and Infectious Disease, 2022 - Elsevier
We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-
nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS …
nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS …
[HTML][HTML] Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis on randomized controlled trials
C Filippatos, I Ntanasis-Stathopoulos, K Sekeri… - Viruses, 2023 - mdpi.com
Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …
Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
M Wang, B Zhou, Q Fan, X Zhou, X Liao… - Emerging Microbes & …, 2023 - Taylor & Francis
With the ongoing COVID-19 pandemic and the emergence of various SARS-CoV-2 variants,
a comprehensive evaluation of long-term efficacy of antibody response in convalescent …
a comprehensive evaluation of long-term efficacy of antibody response in convalescent …
[HTML][HTML] Low spike antibody levels and impaired BA. 4/5 neutralization in patients with multiple myeloma or Waldenstrom's macroglobulinemia after BNT162b2 booster …
M Rosati, E Terpos, J Bear, R Burns, S Devasundaram… - Cancers, 2022 - mdpi.com
Simple Summary Upon BNT162b2 mRNA vaccinations, multiple myeloma (MM) and
Waldenstrom's macroglobulinemia (WM) patient cohorts on active therapy affecting B cell …
Waldenstrom's macroglobulinemia (WM) patient cohorts on active therapy affecting B cell …
[HTML][HTML] XBB. 1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ. 1.1
S Devasundaram, E Terpos, M Rosati… - American journal of …, 2023 - ncbi.nlm.nih.gov
The COVID-19 virus has evolved significantly from the ancestral WA1/2020 strain over the
past three years with new sublineages, subvariants, and recombinant strains emerging and …
past three years with new sublineages, subvariants, and recombinant strains emerging and …
[HTML][HTML] The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age
BL Cinicola, E Piano Mortari, AM Zicari… - Frontiers in …, 2022 - frontiersin.org
SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory,
comprising specific antibodies and memory B and T cells. Although children are at low risk …
comprising specific antibodies and memory B and T cells. Although children are at low risk …
[HTML][HTML] High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
EM Jacobsen, D Fabricius, M Class, F Topfstedt… - Nature …, 2022 - nature.com
The COVID-19 course and immunity differ in children and adults. We analyzed immune
response dynamics in 28 families up to 12 months after mild or asymptomatic infection …
response dynamics in 28 families up to 12 months after mild or asymptomatic infection …